ARCHIVES

SPORE Eligibility, Cost Issues Clarified In Addendum To RFA

This article is from The Cancer Letter archive.

Vol. 17 No. 41 | October 25, 1991

Download PDF Visit The Full Archive

Related Articles

Endostatin Enters Phase II Trial For Neuroendocrine Tumors.

December 14, 2001

NIH Open “One-Stop Shop” For Mutant Mouse Models.

July 20, 2001

CCIRC Told Group Radiation Studies Cost $20,000 Per 25 Patients

March 14, 1980

Children With Recurrent Hodgkin’s Respond To Gemcitabine, Vinorelbine

March 27, 2009

In Brief: Reynolds Retires “Joe Camel” advertising; Slaga Moves Lab To MC Cancer Center

July 18, 1997

Basic Biology Progress, Improved Survival Since 1971 Described By DeVita At Senate Hearing

February 27, 1981